Trial reportGenetic testing and molecular biomarkers2011
Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility.
Trial report in Genetic testing and molecular biomarkers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.Journal of neural transmission (Vienna, Austria : 1996) · 2019Pooled it
- Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment.BMC medical informatics and decision making · 2018Trial
- Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening.PloS one · 2018Trial
- Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.Pharmacogenomics · 2017Trial
- Value of Knowing the Risk of Developing a Neurodegenerative Disease: A Discrete Choice Experiment.PharmacoEconomics · 2026Article
- Examining the Decision to Take a Dementia Risk Test: Considerations for Privacy in Screening At-Home.Dementia and geriatric cognitive disorders · 2026Article
- Apoe genotype knowledge and its impact on cognitive beliefs and performance.Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition · 2026Article
- Is there a "pandemic effect" on individuals' willingness to take genetic tests?European journal of human genetics : EJHG · 2023Article
- Attitudes toward pre-symptomatic screening for Alzheimer's dementia in five European countries: a comparison of family members of people with Alzheimer's dementiaFrontiers in genetics · 2023Article
- On the determinants and the role of the payers in the uptake of genetic testing and data sharing in personalized health.Frontiers in public health · 2023Article
- Views on the Desirability of Diagnosing Sporadic Cerebral Amyloid Angiopathy with Biological Evidence.Journal of Alzheimer's disease : JAD · 2022Article
- People's interest in brain health testing: Findings from an international, online cross-sectional survey.Frontiers in public health · 2022Article
- A survey of aortic disease biorepository participants' preferences for return of research genetic results.Journal of genetic counseling · 2021Article
- Private payer coverage policies for ApoE-e4 genetic testing.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- Physician and patient determinants of prognostic counseling in idiopathic REM sleep-behavior disorder.Sleep medicine · 2019Article
- Genesurance Counseling: Genetic Counselors' Roles and Responsibilities in Regards to Genetic Insurance and Financial Topics.Journal of genetic counseling · 2018Article
- The importance of preventative medicine in conjunction with modern day genetic studies.Genes & diseases · 2018Review
- Article
- The price of whole-genome sequencing may be decreasing, but who will be sequenced?Personalized medicine · 2017Article
- Integrating pharmacogenetic testing into primary care.Expert review of precision medicine and drug development · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe increased availability of genetic tests for common, complex diseases, such as Alzheimer's disease (AD), raises questions about what people are willing to pay for these services.
methodsWe studied willingness-to-pay for genetic testing in a study of AD risk assessment that included APOE genotype disclosure among 276 first-degree relatives of persons with AD.
resultsSeventy-one percent reported that they would ask for such testing from their doctor if it were covered by health insurance, and 60% would ask for it even if it required self-pay. Forty-one percent were willing to pay more than $100 for testing, and more than half would have been willing to pay for the test out of pocket. Participants who learned that they were APOE ε4 positive and those who had higher education were less likely to want testing if covered by insurance, possibly to avoid discrimination.
conclusionThis is the first report to examine willingness to pay for susceptibility genetic testing in a sample of participants who had actually undergone such testing. These findings reveal that some participants find valuable personal utility in genetic risk information even when such information does not have proven clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.